Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Colgate-Palmolive Company (NYSE: CL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings provide detailed information on Colgate-Palmolive’s Oral Care, Personal Care, Home Care and Pet Nutrition businesses, its financial performance and its capital structure.
Colgate-Palmolive’s 8-K filings illustrate how the company uses SEC reports to communicate material events. For example, an 8-K dated November 10, 2025 describes the execution of an underwriting agreement and the issuance of €600,000,000 of 3.250% Senior Notes due 2035 under an automatic shelf registration statement. Other 8-Ks furnish quarterly earnings press releases and explain multi-year productivity initiatives, such as the Strategic Growth and Productivity Program designed to support the company’s 2030 strategy by aligning its organizational structure, optimizing its global supply chain and streamlining overhead.
Filings also list Colgate-Palmolive’s securities registered under Section 12(b) of the Exchange Act, including its common stock (ticker CL) and various series of notes traded on the New York Stock Exchange. Through proxy statements and other periodic reports, investors can review topics such as segment reporting, non-GAAP financial measures like Base Business and organic sales growth, and risk factor disclosures.
On Stock Titan, these SEC documents are updated from EDGAR and paired with AI-powered summaries that highlight key points, such as changes in capital allocation, new debt offerings, productivity program charges or revisions to guidance. Users can quickly scan filings for material information while retaining access to the complete original documents for deeper analysis.
Colgate-Palmolive Company is planning a legal leadership transition. Jennifer M. Daniels, Chief Legal Officer and Secretary since 2014, has informed the company of her intention to retire in 2026. On April 8, 2026, the Board elected Betsy Fishbone, currently Executive Vice President and Deputy Chief Legal Officer, to become Chief Legal Officer and Secretary effective June 1, 2026. On the same date, the Board elected Ms. Daniels as Vice Chair of the company, also effective June 1, 2026, to support an orderly handover of her responsibilities to Ms. Fishbone.
NORRINGTON LORRIE M reported acquisition or exercise transactions in this Form 4 filing.
COLGATE PALMOLIVE CO director Lorrie M. Norrington received an equity award of 294 shares of Common Stock, valued at $89.05 per share. The award represents a portion of her annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, and increases her direct holdings to 40,160 shares.
Newman Brian reported acquisition or exercise transactions in this Form 4 filing.
Colgate-Palmolive director Brian Newman received 210 shares of Common Stock as a grant on April 1, 2026, at $89.05 per share. The award represents a portion of his annual cash retainer deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
After this grant, he directly holds 5,534 shares of Colgate-Palmolive Common Stock. In addition, 36 shares are held indirectly through a family trust. This filing reflects routine director compensation rather than an open-market purchase or sale.
Colgate-Palmolive director John P. Bilbrey acquired 266 shares of Common Stock as a compensation award. The shares, valued at $89.05 each, represent a portion of his annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.
After this grant, he directly holds 37,665 Colgate-Palmolive shares and has an additional 4,719 shares held indirectly by a trust. The transaction reflects routine director compensation rather than an open-market purchase.
Colgate-Palmolive Co: The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting 0 shares of Colgate-Palmolive common stock (0%). The filing states Vanguard completed an internal realignment on January 12, 2026 and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
Colgate-Palmolive Company is asking stockholders to vote at its 2026 virtual Annual Meeting on May 8, 2026. Investors are being asked to elect ten director nominees, ratify PricewaterhouseCoopers as independent auditor, and approve an advisory vote on executive compensation, while the Board recommends voting against two stockholder proposals.
The proxy describes a refreshed 2030 strategy focused on organic sales growth, earnings and free cash flow, supported by brand reach, science-based innovation, omni-channel demand generation, data and AI capabilities, and an inclusive culture. It highlights strong governance practices, a largely independent and diverse Board, robust risk and cybersecurity oversight, and a pay-for-performance executive compensation program where most senior pay is variable and equity-based. Sustainability, climate targets and human capital development are presented as integral to long-term value creation.
Colgate-Palmolive Company director Christopher S. Boerner has filed an initial Form 3 insider ownership report. The summarized data shows no reported buy or sell transactions, no derivative exercises, and no gift, tax, or restructuring entries in this filing excerpt.
Colgate-Palmolive Company is changing how it reports its business segments as part of its Strategic Growth and Productivity Program. Effective for the quarter ending March 31, 2026, the former Europe and Africa/Eurasia segments (excluding Russia and Belarus) and the Skin Health business will be combined into a new Europe, Middle East and Africa reportable segment. Russia and Belarus will now be included in the Asia Pacific reportable segment.
The company states this realignment does not affect its historical consolidated results of operations, financial position or cash flows. For consistency, it has recast historical geographic segment information. In the recast data, total net sales were $20,382 million with operating profit of $3,306 million for the year ended December 31, 2025, and total net sales were $19,457 million with operating profit of $3,984 million for the year ended December 31, 2023.
Colgate-Palmolive Company reported board changes centered on leadership expertise. On March 12, 2026, the board elected Christopher S. Boerner, Ph.D., Board Chair and Chief Executive Officer of Bristol-Myers Squibb Company, as a director effective March 15, 2026. He will be compensated under Colgate-Palmolive’s existing non-employee director compensation program as described in its March 26, 2025 proxy statement.
On the same date, director Steven A. Cahillane informed the board that he will not stand for reelection at the Annual Meeting of Stockholders scheduled for May 8, 2026, due to the demands of his new role as Chief Executive Officer of The Kraft Heinz Company.